



## Advances in Systemic Immunotherapies of Melanoma and Other Cancers

Guest Editor:

**Dr. Brendon J. Coventry**

Department of Surgery,  
University of Adelaide, Adelaide,  
Australia

Deadline for manuscript  
submissions:  
**closed (20 September 2023)**

### Message from the Guest Editor

Dear Colleagues,

Our understanding of cancer genesis and control has taken another leap forward with recent advances in immunotherapies and our knowledge of the role of the immune system in cancer modulation.

This has provided some novel conceptual models explaining the complexity of the cancer microenvironment and its interaction with the immune system in a bimodal manner, meaning it is able to modulate either activation or tolerance, the balance of which impacts the clinical outcome.

Our comprehension of this dynamic interaction between cancer cells, stroma and the immunological system is just beginning, and the mechanisms involved are gradually being elucidated. Emerging observations of “local” versus “systemic” cancer control are rapidly leading to the revelation that there is much overlap and synergy, inviting the development of new concepts of “systemic” cancer therapy.

In this Special Issue, we aim to bring together some fascinating concepts and approaches to clinical cancer treatments and the underlying mechanisms for modulating the immune system to add to the rapidly accumulating substantial evidence based on cancer immunotherapies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)